A proven track record of value creation
We are a multinational pharmaceutical company with a local presence across North America and Canada, MENA and Europe, providing our customers with a broad range of generic, specialty and branded pharmaceutical products
Full year 2025 results
Khalid Nabilsi, Deputy CEO, North America and Europe
Our purpose is to put better health within reach, every day
Sustainability reporting
We are dedicated to ensuring patients across the US, Canada, Europe, and the MENA region have access to high-quality medicines. Our mission is to advance health and wellbeing by empowering our people, protecting the environment, and operating with transparency and ethically.
Annual Report
Ensuring patients have access to the medicines they need is at the heart of everything we do. In 2025, we continued to invest in our people, capabilities, and infrastructure to strengthen our ability to deliver high-quality, affordable medicines across the communities we serve.
Latest news
Hikma delivers Group revenue and profit growth and announces share buyback and leadership changes
- Hikma launches authorised generic of Nucynta® ER (tapentadol) extended-release in the US Press Release, Product 11 March 2026 Hikma launches authorised generic of Nucynta® ER (tapentadol) extended-release in the US
- Hikma delivers Group revenue and profit growth and announces share buyback and leadership changes Press Release, Financial Results 26 February 2026 Hikma delivers Group revenue and profit growth and announces share buyback and leadership changes
- Hikma launches authorised generic of Nucynta® (tapentadol) in the US Press Release, Product 25 February 2026 Hikma launches authorised generic of Nucynta® (tapentadol) in the US
- Notice of results Press Release, Financial Results 03 February 2026 Notice of results